Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Zykadia 150mg hard capsules {equilateral_black_triangle}

Discontinued
Active Ingredient:
ceritinib
Company:  
Novartis Pharmaceuticals UK Ltd See contact details
ATC code: 
L01XE28
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Product Information Live Chat HCP Med Info
{arrow_left}
{arrow_right}
Important Note Regarding Zykadia Patient Information Leaflets

Zykadia packs containing the now superseded Patient Information Leaflet may continue to be dispensed to patients. These packs contain a leaflet advising patients of the fasted dosing regimen and the starting dose of 750 mg. Please alert patients starting on, or transitioning, to the new 450 mg fed dosing regimen of this fact.

Zykadia®▼ (ceritinib) 150 mg Capsules replaced by Zykadia 150 mg film coated Tablets

Please note Zykadia®▼ (ceritinib) 150 mg Capsules are no longer available to order and have been replaced by Zykadia 150 mg film coated Tablets. The Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL) for Zykadia Capsules remains available for those currently using any remaining stock of the capsules. If you require any further information, please do not hesitate to contact the Medical Information Department on 01276 698370.
Novartis Pharmaceuticals UK Ltd
Company image
Address
2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ
Telephone
+44 (0)1276 692 255
E-mail
[email protected]
Medical Information Direct Line
+44 (0)1276 698 370
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)845 741 9442